Rare and Orphan Diseases - Global Cardiology Academy

17-32 of 59

Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Heart Matters
Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Disease-Modifying Advances in ATTR-CM Management
Disease-Modifying Advances in ATTR-CM Management
Heart Matters
Disease-Modifying Advances in ATTR-CM Management
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
AudioAbstracts
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
Ryan Quigley
- Ryan Quigley
AI-Driven Advances in ATTR-CM Care
AI-Driven Advances in ATTR-CM Care
Heart Matters
AI-Driven Advances in ATTR-CM Care
Frederick Ruberg, MD
- Frederick Ruberg, MD
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
On the Frontlines of ATTR-CM
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
Shelina Ramnarine, PhD; Chadi Alraies, MD, MPH, FACC
- Shelina Ramnarine, PhD
- Chadi Alraies, MD, MPH, FACC
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
On the Frontlines of ATTR-CM
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
Ryan Quigley; Ahmad Masri, MD, MS
- Ryan Quigley
- Ahmad Masri, MD, MS
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Heart Matters
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Ahmad Masri, MD, MS
- Ahmad Masri, MD, MS
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
On the Frontlines of ATTR-CM
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
Ryan Quigley; Kevin Alexander, MD
- Ryan Quigley
- Kevin Alexander, MD
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Heart Matters
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Kevin Alexander
- Kevin Alexander
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
On the Frontlines of ATTR-CM
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
Ryan Quigley; Quan Bui, MD
- Ryan Quigley
- Quan Bui, MD
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Heart Matters
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Quan Bui, MD
- Quan Bui, MD
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Heart Matters
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
AudioAbstracts
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
Hallie Blevins, PhD
- Hallie Blevins, PhD
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
AudioAbstracts
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
Hallie Blevins, PhD
- Hallie Blevins, PhD
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
Heart Matters
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
Heart Matters
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit

2/4